The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Targeting HER2 in colorectal cancer
John H. Strickler, MD, Duke Cancer Institute, Durham, NC, talks on HER2 as a target in patients with colorectal cancer (CRC). The HER2-targeted antibody-drug conjugate (ADC) trastuzumab combined with tucatinib achieved promising results in the Phase II MOUNTAINEER trial (NCT03043313) in previously treated HER2+ metastatic colorectal cancer (mCRC). The combination demonstrated an objective response rate (ORR) of 38.1% and a duration of response (DoR) of 12.4 months. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Transcript
So, this is an exciting time for research in colorectal cancer as well. For HER2 positive colorectal cancer, we’ve already seen very favorable efficacy from the antibody drug conjugate, trastuzumab deruxtecan. Additionally, initial results of looking at tucatinib and trastuzumab in patients with HER2 positive colorectal cancer have been favorable. We look forward to presenting the full results of the MOUNTAINEER trial, which examines tucatinib and trastuzumab in HER2 positive colorectal cancer...
So, this is an exciting time for research in colorectal cancer as well. For HER2 positive colorectal cancer, we’ve already seen very favorable efficacy from the antibody drug conjugate, trastuzumab deruxtecan. Additionally, initial results of looking at tucatinib and trastuzumab in patients with HER2 positive colorectal cancer have been favorable. We look forward to presenting the full results of the MOUNTAINEER trial, which examines tucatinib and trastuzumab in HER2 positive colorectal cancer. Those results will be shown in early July at ESMO World GI. It is my hope that one day, we will have several FDA approved options for these patients with HER2 positive colorectal cancer. And ultimately, we are becoming much smarter about how we treat colorectal cancer in-general. Picking individual biomarkers with highly active therapies, and then matching that patient with the best available therapy to reduce toxicity, and also to help them live with a better quality of life. So, that’s an exciting development.
Read more...
